Long-Term Melatonin Use Tied to Higher Heart Failure Risk in Chronic Insomnia
Melatonin has become one of the most familiar sleep aids on pharmacy shelves, often treated like a benign nightly habit rather than a drug with biologic consequences. A preliminary study in people with chronic insomnia now raises a more sobering concern: long-term users of melatonin had a roughly 90% higher risk of developing heart failure over five years.
The signal does not prove cause and effect, and it does not mean every person who takes melatonin is moving toward cardiac disease. It does, however, place a commonly used hormone supplement under a sharper cardiovascular lens, especially for patients who remain on it for months or years without clear medical supervision.
Five-Year Risk Signal in Chronic Insomnia
The study examined people with chronic insomnia who used melatonin long term and compared their outcomes with those who did not. Over a five-year period, the melatonin group experienced a markedly higher incidence of heart failure, with risk estimates landing at roughly 90% above the comparison group. The magnitude of the association is large enough to demand attention, even in a preliminary dataset.
One sentence captures the clinical tension here: a supplement chosen for sleep may be tracking with one of cardiology’s most consequential diagnoses.
The finding is especially relevant because melatonin is often viewed as a low-stakes option, including by patients who would never consider long-term prescription hypnotics. That perception can lead to years of continuous use, particularly when insomnia is chronic and untreated underlying drivers — sleep apnea, depression, circadian disruption, pain, or stimulant use — remain in place. In that setting, melatonin can become a default maintenance therapy rather than a short-term bridge.
Why a Sleep Hormone Could Matter to the Heart
Melatonin is not merely a sedative. It is a hormone that helps coordinate circadian timing, and circadian biology is deeply intertwined with cardiovascular regulation. Blood pressure, autonomic tone, vascular reactivity, glucose handling, and inflammatory signaling all vary across the day-night cycle. Interfering with that system for long periods could plausibly affect myocardial loading conditions, endothelial function, or downstream remodeling pathways, even if the precise mechanism remains unproven in this study.
Another possibility is more indirect. People who rely on long-term melatonin may represent a group with more severe insomnia or greater underlying illness burden than nonusers. Chronic sleep disruption itself can elevate sympathetic activation and worsen cardiometabolic health, making the medication a marker of risk rather than the cause. Distinguishing those possibilities requires better-controlled studies, not assumptions.
The clinical question is not whether melatonin is toxic in every circumstance. The question is whether chronic, unsupervised exposure is being used as a substitute for diagnosis, and whether that substitution carries a hidden cardiovascular cost.
What the Association Can and Cannot Support
This preliminary study cannot establish causality. It also cannot determine whether the risk was driven by dose, formulation, duration of use, adherence patterns, or the severity of baseline insomnia. Those details matter because melatonin products vary widely across the market, and over-the-counter use often escapes the documentation that would be routine for a prescription drug.
Even so, a five-year association of this size should not be dismissed as a statistical curiosity. Heart failure is not a vague endpoint; it is a syndrome that often follows years of hemodynamic stress, neurohormonal activation, and structural remodeling of the heart. If melatonin use is a marker for a physiological state that promotes those pathways, the association could still have practical value in risk stratification.
For bedside care, the first move is not panic. It is medication reconciliation.
Patients with insomnia frequently take melatonin without mentioning it, especially if they consider it a vitamin-like aid rather than an active hormone. That omission matters when clinicians are reviewing causes of fatigue, edema, dyspnea, poor exercise tolerance, or unexplained weight gain. A careful sleep history should include duration of use, nightly dose, timing, and whether melatonin is being taken alongside other sleep agents, antidepressants, antihypertensives, or alcohol.
Insomnia Management May Need a Different Conversation
The result also reinforces a broader point about insomnia care: symptom suppression is not the same as treatment. If a patient has chronic sleep difficulty, the underlying reason deserves evaluation rather than indefinite automatic supplementation. Cognitive behavioral therapy for insomnia, circadian interventions, treatment of sleep apnea, pain control, and psychiatric assessment often provide a more durable path than continued self-directed hormone use.
For cardiology and primary care alike, the practical implication is to ask a harder question when melatonin appears on the medication list. Is this a short-term adjunct, or has it become a standing medication for a disorder that has never been fully characterized? In patients with cardiovascular risk factors, the answer could influence how aggressively sleep problems are addressed and how closely symptoms are followed.
No current result justifies abrupt alarm, but the study does challenge a comfortable assumption. A supplement long marketed as gentle and harmless now sits beside a serious cardiovascular endpoint, and the gap between perception and biology may be wider than many patients realize. Future research will need to separate insomnia severity from drug effect, test whether risk differs by formulation or dose, and determine whether the association persists in more rigorously controlled cohorts.